Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

Company Overview - Femasys Inc. is a leading biomedical innovator focused on women's health, offering a range of therapeutic and diagnostic products [1][4] - The company is based in Atlanta and manufactures all its products in the U.S. [4] Patent Developments - The European Patent Office has issued notices of intention to grant for two EU Patent Applications, with anticipated expirations in 2039 and 2038 [1] - Femasys plans to pursue additional patent applications to strengthen its portfolio, particularly for FemBloc® permanent birth control and other products [1][2] Product Highlights - FemBloc® is a non-surgical permanent birth control method that uses a minimally invasive delivery system to block fallopian tubes [3] - The product is designed to be safe, accessible, and cost-effective compared to traditional surgical sterilization [3] - Femasys is currently enrolling participants in a pivotal clinical trial for U.S. approval of FemBloc® [3][4] Regulatory Approvals - Femasys has received global regulatory approvals for its products, including FemaSeed®, FemVue®, FemCerv®, and FemCath® [4] - FemBloc® is positioned as a late-stage product candidate, with significant benefits over surgical alternatives [4]